Fintech PR
Ping An Chairman Dr. Ma Mingzhe Receives Director of The Year Award from The Hong Kong Institute of Directors
![ping-an-chairman-dr.-ma-mingzhe-receives-director-of-the-year-award-from-the-hong-kong-institute-of-directors](https://thefintechbuzz.com/wp-content/uploads/2023/11/47603-ping-an-chairman-dr-ma-mingzhe-receives-director-of-the-year-award-from-the-hong-kong-institute-of-directors.png)
HONG KONG and SHANGHAI, Nov. 26, 2023 /PRNewswire/ — Ping An Insurance (Group) Company of China, Ltd. (hereafter “Ping An”, the “Company” or the “Group”, HKEX: 2318 / 82318; SSE: 601318) is pleased to announce that Dr. Ma Mingzhe, Chairman of Ping An, has been honored by The Hong Kong Institute of Directors. His Director of the Year Award 2023 in the Listed Companies Executive Directors category recognizes his exemplary leadership and innovative approaches in corporate governance at Ping An. This is the fourth time Dr. Ma has received this prestigious award.
The panel of judges from The Hong Kong Institute of Directors unanimously praised Dr. Ma for his exceptional leadership and foresight, saying: “Dr. Ma is a seasoned and open-minded board chairman with strong commercial acumen. He is focused on long-term strategic planning, talent management, and corporate governance. He fully understands the importance of succession planning at the board and management levels. He has a good sense of external environments. Under his leadership, Ping An consciously adopts ESG investment philosophies to enhance its post-investments. Dr Ma absolutely deserves the Award.”
Dr. Ma said: “The Director of the Year Awards bestowed by the Hong Kong Institute of Directors stand as a pillar of professionalism and authority within our industry. It is with immense honor and pride that I accept this award for the fourth time. This accolade serves as an affirmation of Ping An’s steadfast commitment to stringent corporate governance and the collective endeavor of our esteemed board members. Throughout our 35-year venture, Ping An has relentlessly pursued a pinnacle of excellence, by integrating global best practices in corporate governance and tailor-making them to suit our local context in China. We have a meticulously constructed framework that not only complies with international standards but also recognizes the unique local characteristics. We have placed significant emphasis on fostering visionary leadership and advancing sustainable long-term progress. This honor is not only a recognition but also a source of inspiration for us. We pledge to maintain high standards of corporate governance, further enhance our strategic management prowess, and remain focused on our “Integrated Finance + Healthcare and Elderlycare” strategy. As we strive to augment the quality of our core business operations, our unweaving dedication is to generate lasting value for our clients, shareholders, employees, and the society we serve.”
Ping An’s Board of Directors focuses on the foresight, guidance and accuracy of the Company’s strategy, prioritizes long-term and sustainable development and captures development opportunities. It remains focused on customer needs and enhancing its digital prowess to foster high-quality growth. By the end of September 2023, the Company had nearly 230 million retail customers, with an average of 2.99 contracts per customer. It has made significant strides in life insurance reform, and the innovative changes implemented over the past three years led to a 40.9% year-on-year increase in the new business value of life and health insurance to RMB33.574 billion in the first three quarters of 2023. In addition, the Company’s healthcare and elderlycare services are progressing well. Customers entitled to ‘+ services’ benefits in the healthcare ecosystem accounted for approximately 68% of Ping An Life’s new life insurance business value in the first three quarters of 2023.
Ping An’s Board is also proactively addressing the challenges and prospects arising from climate change. It continues to advance its green finance initiative and uphold its social responsibilities to guarantee sustained stable business growth. By the end of June 2023, green investment in Ping An’s insurance assets reached RMB140.929 billion, while the balance of green loans stood at RMB134.926 billion. During the first three quarters of 2023, the company’s green insurance policies generated original premium income of RMB26.276 billion. Ping An has also committed a total of RMB103.241 billion to aid in rural industrial assistance through its Rural Communities Support programs since 2018.
Ping An emphasizes that, guided by its board, the Company is committed to further developing its “integrated finance + healthcare” strategy, driven by technology. This approach aims to strengthen the synergies within integrated finance while actively enhancing its healthcare and elderlycare offerings. The Company is also dedicated to elevating its operational management standards, advancing digital transformation across the board, and focusing on cost-effective and efficient practices. This strategy is designed to foster high-quality development and consistently generate substantial value for its customers, employees, shareholders, and society.
The Directors of the Year Awards, the first of its kind, have been held annually by The Hong Kong Institute of Directors since 2001. It is dedicated to recognizing outstanding boards and directors, highlighting the significance of good corporate governance, and promoting director professionalism and excellence.
About Ping An Group
Ping An Insurance (Group) Company of China, Ltd. (HKEx:2318 / 82318; SSE:601318) strives to become a world-leading integrated finance and healthcare services provider. With nearly 230 million retail customers, Ping An is one of the largest financial services companies in the world. Under the technology-driven “integrated finance + healthcare” strategy, Ping An provides professional “financial advisory, family doctor, and elderlycare concierge” services. Ping An advances intelligent digital transformation and employs technologies to improve the quality and efficiency of its financial businesses and enhance risk management. The Group is listed on the stock exchanges in Hong Kong and Shanghai. As of the end of 2022, Ping An had RMB11,137,168 million in total assets. The Group ranked 16th in the Forbes Global 2000 list in 2023 and ranked 33rd in the Fortune Global 500 list in 2023.
For more information, please visit www.group.pingan.com and follow us on LinkedIn – PING AN.
View original content:https://www.prnewswire.co.uk/news-releases/ping-an-chairman-dr-ma-mingzhe-receives-director-of-the-year-award-from-the-hong-kong-institute-of-directors-301997464.html
Fintech PR
Invitation to presentation of EQT AB’s Q1 Announcement 2024
![invitation-to-presentation-of-eqt-ab’s-q1-announcement-2024](https://thefintechbuzz.com/wp-content/uploads/2024/04/51875-invitation-to-presentation-of-eqt-abs-q1-announcement-2024.png)
STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.
The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.
To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.
The webcast can be followed live here and a recording will be available afterwards.
Information on EQT AB’s financial reporting
The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.
The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.
Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]
Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826
The following files are available for download:
Invitation to presentation of EQT AB’s Q1 Announcement 2024 |
|
EQT AB Group |
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html
Fintech PR
Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs
![kia-presents-roadmap-to-lead-global-electrification-era-through-evs,-hevs-and-pbvs](https://thefintechbuzz.com/wp-content/uploads/2024/04/51877-kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs.jpg)
- Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
- Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
- Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
- Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
- 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
- CEO reaffirms Kia’s commitment to ESG management
SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.
Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.
During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.
The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.
“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”
Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html
Fintech PR
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
![biovaxys-technology-corp.-provides-bi-weekly-mcto-status-update](https://thefintechbuzz.com/wp-content/uploads/2024/04/51873-biovaxys-technology-corp-provides-bi-weekly-mcto-status-update.jpg)
VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.
Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054
Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html
-
Latest News6 days ago
“Grand Huangshan” Debuts at the 2024 World Brand Moganshan Conference
-
Latest News6 days ago
AI-powered Panax raises $15m to reshape cash flow management
-
Latest News7 days ago
Yili’s 2023 Revenue Reaches 126.2 Billion Yuan, Leading Global Dairy Industry towards Healthy and Sustainable Development
-
Latest News6 days ago
Egypt’s Swypex launches an all-in-one fintech platform after $4m seed round
-
Latest News6 days ago
Sweden’s Mitigram names Pedram Tadayon as new CEO
-
Latest News6 days ago
Sobha Developers bring to Singapore an Exclusive Dubai Property Showcase
-
Latest News6 days ago
South African fintech Lesaka snaps up Adumo in $86m deal
-
Latest News5 days ago
Al Hassan Ghazi Ibrahim Shaker Co. announces a strong start to FY24, reporting a 12.09% YoY increase in net profit to reach SAR 32.25 million in Q1-FY24